Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Represents Emergent BioSolutions in $270M Acquisition

August 9, 2018

WASHINGTONCovington advised Emergent BioSolutions in its $270 million acquisition of PaxVax. PaxVax is majority owned by an affiliate of Cerberus Capital Management.

Emergent is a global life sciences company focusing on providing specialty products for civilian and military populations that address public health threats. PaxVax is a company focused on specialty vaccines that protect against existing and emerging infectious diseases.

The Covington team included Michael Riella, Catherine Dargan, and Joseph Gangitano (M&A); Denise Esposito and Allison Whelan (regulatory); Miranda Cole, James Dean, and James O'Connell (antitrust); Michael Francese (employment); Ansgar Simon and Daniel Luchsinger (tax); Amy Toro (life sciences); Heather Haberl (real estate); and Marie Lavalleye (intellectual property).

Share this article: